Compare AbCellera Biologics Inc (ABCL) vs Equinix Inc (EQIX) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbCellera Biologics Inc vs Equinix Inc — how do they compare? AbCellera Biologics Inc trades at $7.18 (market cap $2.35B), while Equinix Inc trades at $1,019.99 (market cap $100.89B). The key difference: Equinix Inc is far larger — about 42.9× AbCellera Biologics Inc's market cap, and Equinix Inc pays a 1.93% dividend while AbCellera Biologics Inc pays none. Which is the better fit depends on your goals.
| ABCL | EQIX | |
|---|---|---|
Market Cap | $2.35B | $100.89B |
Sector | Health | Real Estate |
52-Week High | $8.12 | $1.12K |
52-Week Low | $2.78 | $726.09 |
Enterprise Value | $1.99B | $121.17B |
Dividend Yield | — | 1.93% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.
The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.
Equinix (EQIX) trades at $1,022.93, up 2.09% today, with a bearish technical signal despite recent AI partnership news. The stock shows strong revenue growth to $9.22B in 2025 and a net income margin of 15.07%, but faces high valuation multiples (P/E 69.08) and negative net cash flow. Analyst consensus is strongly bullish with a $1,190 price target, though recent earnings misses and elevated debt levels pose concerns.
Outlook remains mixed: AI infrastructure demand offers growth potential, but high leverage and valuation compression risks weigh on near-term upside. Investors should balance strong institutional support against execution risks and macroeconomic headwinds affecting capital-intensive expansions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About Equinix Inc
Equinix is a retail provider of data centers, enabling hundreds of enterprise tenants to house their servers and networking equipment in a collocated environment. Tenants can then connect with each other, through cloud service providers and telecom networks. Equinix operates 240 data centers in 66 markets worldwide and owns just less than half of them. The firm has roughly 10,000 customers, including 2,000 networks, that are dispersed over five verticals: Cloud and IT Services, Content Providers, Network and Mobile Services, Financial Services, and Enterprise. About 70% of Equinix's revenue comes from renting space to tenants and related services, and more than 15% comes from connecting customers with each other. Equinix operates as a real estate investment trust.
Read more on EQIX →
